The history of Sildenafil presents a challenging picture for shareholders. While the initial launch generated significant returns, the lapse of its exclusive rights opened the avenue to cheaper competitors, https://followbookmarks.com/story21758417/the-copyright-and-pharma-a-volatile-bet